

## Business performance (Full Year) [IFRS]

(millions of yen)

	2016/3	2017/3	2018/3	2019/3	2020/3	2021/3	2022/3	2023/3	2024/3	2025/3
<b>Continuing Operations</b>										
Revenue	1,031,740	962,555	1,031,256	1,059,120	996,101	863,381	911,426	1,130,397	1,159,999	1,127,882
Cost of sales	536,226	502,616	541,453	550,231	529,780	488,726	518,689	644,453	655,322	648,462
Gross profit	495,514	459,938	489,803	508,888	466,321	374,654	392,736	485,943	504,676	479,420
Other income	7,786	14,147	24,856	25,402	4,615	14,031	10,274	6,533	15,188	12,028
Selling, general and administrative expenses	429,891	416,622	443,996	458,194	443,071	389,672	404,890	456,204	478,656	447,492
Other expenses	13,339	7,328	16,819	13,652	19,654	15,280	20,418	131,398	15,116	107,970
Operating profit (loss)	60,069	50,135	53,844	62,444	8,211	-16,266	-22,297	-95,125	26,091	-64,014
Finance income	2,155	2,724	3,778	6,091	4,923	5,010	6,892	4,024	3,116	3,273
Finance costs	4,179	3,451	7,851	7,772	12,594	8,756	8,211	10,675	15,405	18,420
Share of profit (loss) of investments accounted for using the equity method	-16	-66	-647	-624	-255	12	-	-96	-236	4
Profit(loss) before tax	58,029	49,341	49,124	60,138	284	-20,000	-23,617	-101,872	13,566	-79,156
Income tax expense (income)	26,029	17,856	16,916	18,409	3,371	-5,349	2,589	1,944	9,366	16,229
Profit (loss) from Continuing Operations	32,000	31,485	32,207	41,729	-3,086	-14,650	-26,206	-103,816	4,199	-95,386
<b>Discontinued Operation</b>										
Profit (loss) from Discontinued Operation	-	-	-	-	-	-	-	-	-1,321	45,069
Profit (loss) for the year	-	-	-	-	-	-	-	-	4,199	-50,316
<b>Profit attributable to (loss):</b>										
Owners of the Company	31,973	31,542	32,248	41,705	-3,073	-15,211	-26,123	-103,153	4,521	-47,484
Non-controlling interensts	26	-56	-41	24	-12	560	-83	-663	-321	-2,832
<b>Earnings (loss) per share</b>										
Basic (loss) (yen)	64.39	63.65	65.17	84.33	-6.21	-30.75	-52.93	-208.89	9.15	-95.98
Diluted (loss) (yen)	64.21	63.47	64.96	84.03	-6.21	-30.75	-52.93	-208.89	9.12	-95.98

**Business performance (Quarter) [IFRS]**

(millions of yen)

	2025/3 Q2	2025/3 Q3	2025/3 Q4	2026/3 Q1
<b>Continuing Operations</b>				
Revenue	297,517	273,953	296,042	251,204
Cost of sales	163,261	153,154	180,926	140,950
Gross profit	134,256	120,799	115,115	110,253
Other income	-567	1,590	7,840	3,866
Selling, general and administrative expenses	118,042	108,343	111,993	101,058
Other expenses	15,964	31,478	56,518	2,998
Operating profit (loss)	-318	-17,432	-45,555	10,062
Finance income	717	2,235	816	1,897
Finance costs	8,582	3,141	5,884	3,071
Share of profit (loss) of investments accounted for using the equity method	-	-	4	2
Profit (loss) before tax	-8,182	-18,339	-50,619	8,891
Income tax expense (income)	-1,053	5,867	9,036	4,268
Profit (loss) from Continuing Operations	-	-24,207	-59,655	4,622
<b>Discontinued Operation</b>				
Profit (loss) from Discontinued Operation	-	21,703	22,581	2,984
Profit (loss) for the period	-7,129	-2,503	-37,074	7,606
<b>Profit (loss) attributable to:</b>				
Owners of the Company	-7,261	-2,685	-34,084	7,283
Non-controlling interests	132	181	-2,989	322
<b>Earnings (loss) per share</b>				
Basic (yen)	-14.69	-5.42	-68.89	14.74
Diluted (yen)	-14.69	-5.42	-68.89	14.70

The Precision Medicine Business is classified as a discontinued operation from the nine months ended December 31, 2024. As a result, revenue, business contribution profit, operating profit, and profit before tax represent the amount of continuing operations excluding the discontinued operation. Profit for the period and profit attributable to owners of the Company represent the sum of continuing operations and the discontinued operation.

**Business performance (Latest 10 years) [J-GAAP]**

(millions of yen)

	Mar-06	Mar-07	Mar-08	Mar-09	Mar-10	Mar-11	Mar-12	Mar-13	Mar-14	Mar-15
Net sales	1,068,390	1,027,630	1,071,568	947,843	804,465	777,953	767,879	813,073	943,759	1,011,774
Cost of sales	575,163	532,714	540,225	520,206	439,978	423,372	412,562	437,487	492,269	513,982
Gross profit	493,227	494,916	531,343	427,637	364,486	354,580	355,317	375,585	451,490	497,791
Selling, general and administrative expenses	409,811	390,909	411,736	371,376	320,498	314,558	314,971	334,926	393,346	431,591
Operating income	83,415	104,006	119,606	56,260	43,988	40,022	40,346	40,659	58,144	66,200
Non-operating income										
Interest income	1,756	2,316	2,227	1,655	1,749	1,434	1,095	1,051	1,641	1,689
Dividends income	-	-	415	520	358	372	468	424	480	844
Equity in earnings of affiliates	-	-	182	-	81	112	67	61	-	35
Foreign exchange gains	5,413	3,432	-	-	-	-	-	1,508	-	-
Other	7,709	8,904	7,766	5,748	5,654	3,975	3,800	4,674	3,437	3,340
Total non-operating income	14,879	14,653	10,592	7,925	7,843	5,895	5,431	7,720	5,559	5,910
Non-operating expenses										
Interest expenses	5,427	5,088	4,465	4,866	3,808	3,129	2,519	2,499	2,852	2,398
Disposal/valuation losses of inventories	7,540	7,054	7,065	-	-	-	-	-	-	-
Equity in losses of affiliates	2,507	160	-	99	-	-	-	-	1,163	-
Foreign exchange losses	-	-	7,637	7,272	1,124	3,762	2,567	-	126	449
Other	5,982	8,255	6,801	6,544	6,079	5,869	5,932	6,978	4,940	7,749
Total non-operating expenses	21,457	20,559	25,970	18,782	11,013	12,761	11,018	9,478	9,083	12,243
Ordinary income	76,838	98,099	104,227	45,403	40,818	33,155	34,758	38,901	54,621	59,867
Extraordinary income										
Total extraordinary income	3,353	11,848	10,047	8,073	3,593	3,477	4,719	388	1,524	4,590
Extraordinary loss										
Total extraordinary losses	116,126	5,058	15,278	20,252	8,329	8,521	6,663	5,454	32,642	9,236
Income before income taxes and minority interests	-35,934	104,890	98,996	33,224	36,082	28,111	32,815	33,836	23,503	55,221
Income taxes-current	24,650	27,307	29,496	13,183	9,306	9,580	9,553	11,745	11,624	14,466
Income taxes-deferred	-7,116	4,827	544	4,857	9,806	-7,420	2,776	6,934	-10,060	8,012
Total income taxes	-	-	30,040	18,040	19,113	2,160	12,330	18,680	1,564	22,479
Income before minority interests	-	-	-	-	-	25,951	20,484	15,155	21,939	32,741
Minority interests in income	837	213	126	5	37	54	60	30	77	35
Net income	-54,305	72,542	68,829	15,179	16,931	25,896	20,424	15,124	21,861	32,706